Anteris Technologies Announces Results for the Second Quarter of 2026
Anteris Technologies reported strong Q2 2026 results, highlighted by securing U.S. Medicare reimbursement eligibility for their pivotal PARADIGM Trial and initiating patient recruitment in the U.S. The trial, designed to evaluate Anteris's DurAVR® Transcatheter Heart Valve (THV) against commercial TAVR devices, is progressing globally with regulato…